AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04996823 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Participants will receive ipilimumab 3mg/kg IV every 3 weeks for up to 4 doses.
Study NCT04996823 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Axitinib
Description: Participants will take 5 mg Axitinib twice daily by mouth for up to 35 cycles (24 months)
Study NCT05293132 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard Treatment
Description: Standard sepsis treatment includes fluid resuscitation, early administration of intravenous broad spectrum antibiotic (ceftriaxone 2gm/24 hour or meropenem 1g/8 hours, linezolid 600/12hours) till obtaining the microbiological culture to narrow the coverage, paracetamol intravenous antipyretic (paracetamol 1gm/8 hours) till no fever and temperature less than 380c, and prophylactic anticoagulant low molecular weight heparin (enoxaparin 40/24 hours), prophylactic stress ulcer (pantoprazole 40mg/24hours)
Study NCT05104554 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Iron and folic acid (IFA)
Description: IFA: Weekly regimen of one tablet containing iron (60 mg) and folic acid (2800 μg)
Study NCT05104554 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Multiple Micronutrient Supplement (MMS)
Description: MMS: Daily regimen of one multiple micronutrient tablet containing fifteen micronutrients in the United Nations International Multiple Micronutrient Preparation (UNIMMAP) preparation. Composition includes vitamin A (800 ug), vitamin D (5 ug), vitamin E (10 mg), vitamin C (70 mg), vitamin B1 (1.4 mg), vitamin B2 (1.4 mg), niacin (18 mg), vitamin B6 (1.9 mg), vitamin B12 (2.6 ug), folic acid (400 ug), iron (30 mg), zinc (15 mg), copper (2 mg), selenium (65 ug), and iodine (150 ug).
Study NCT05293132 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard Treatment
Description: Standard sepsis treatment includes fluid resuscitation, early administration of intravenous broad spectrum antibiotic (ceftriaxone 2gm/24 hour or meropenem 1g/8 hours, linezolid 600/12hours) till obtaining the microbiological culture to narrow the coverage, paracetamol intravenous antipyretic (paracetamol 1gm/8 hours) till no fever and temperature less than 380c, and prophylactic anticoagulant low molecular weight heparin (enoxaparin 40/24 hours), prophylactic stress ulcer (pantoprazole 40mg/24hours)
Study NCT05998824 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: SCD-specific COVID-19 vaccination information (SCVI) video
Description: SCD-specific COVID-19 vaccination information (SCVI) video developed by health care providers with input from a community advisory board of people with sickle cel disease and their caregivers.
Study NCT06269367 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: NewGait
Description: wearable limb orthotic device
Study NCT06269367 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Control wearable limb orthotic device
Description: wearable limb orthotic device
Study NCT05895825 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EOC237
Description: EOC237 for orally
Study NCT06453447 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: 40 mg PO once daily for 14 days starting day of surgery
Study NCT05658536 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: 6-Week Self-Management Group
Description: The goal of the 6-session group-based intervention for patients with Post-COVID is to teach patients behavioral strategies known to be helpful in managing several common Post-COVID symptoms, including fatigue, memory and attention issues, poor sleep, breathlessness, coping with anxiety and uncertainty, and stress management. It is currently available to patients who are seen in the Post-COVID-19 Rehabilitation and Recovery Clinic at UW and the Post-COVID-19 Clinic in VAPSHCS Rehabilitation Care Services.
Study NCT05361057 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax, Azacitidine
Description: The patients were administrated with azacytidine 75 mg/m2 d1-7，venetoclax: 100mg d1, 200mg d2, 400mg d3-21;
Study NCT05361057 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Venetoclax, daunorubicin, cytarabine
Description: The patients were administrated with daunorubicin：45mg/m2 d1-2, cytarabine:100mg/ m2 d1-5, venetoclax: 100mg d1, 200mg d2, 400mg d3-14
Study NCT05407610 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Radiofrequency ablation of the genicular nerves
Description: Conventional Radiofrequency treatment of the genicular nerves of the knee blocks the transmission of painful stimuli from the sensory genicular nerves of the knee to the central nervous system by means of a thermal lesion created using RF current.
Study NCT05407610 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cooled Radiofrequency ablation of the genicular nerves
Description: Cooled RF treatment causes a larger lesion size compared to conventional RF by means of internal cooling of the probe.
Study NCT05407610 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham procedure
Description: Sham procedure with placing of needles subcutaneously.
Study NCT06136247 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Neurocognitive battery
Description: The Penn Computerized Neurobehavioral Battery (CNB) consists of a series of cognitive tasks, measuring accuracy and speed of performance in major cognitive domains, including executive functions (i.e., abstraction, sustained attention, working memory), episodic memory (i.e., verbal, facial, and spatial memory), complex cognitive processing (i.e., language reasoning, nonverbal reasoning, spatial processing), social cognition (i.e., emotion identification, emotion intensity differentiation, age differentiation) and processing speed (i.e., sensorimotor and motor).
Study NCT06136247 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: fNIRS
Description: Functional near-infrared spectroscopy (fNIRS) is a noninvasive optical imaging technique that measures changes in oxygenated and deoxygenated hemoglobin (Hb) concentrations within the brain by means of their characteristic absorption spectra of the wavelengths range of 700-1000 nm \[35,36\].
Study NCT06278389 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACC017 tablets
Description: ACC017 tablets 5 mg, 20 mg, 40 mg, 80 mg, 120 mg, and 160 mg (tentative) with matching placebo
Study NCT06278389 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Emtricitabine and Tenofovir Alafenamide Fumarate Tablets
Description: Participants received a single oral dose of ACC017 tablets with emtricitabine and tenofovir alafenamide fumarate tablets under the fasting condition.
Study NCT01351038 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epirubicine, Oxaliplatin, Capecitabine, Panitumumab
Description: 3 cycles (repeated q 21d) Epirubicine 50mg/m² i.v. d1 Oxaliplatin 100mg/m² i.v. d1 Panitumumab 9mg/kg i.v. d1 Capecitabine 500mg/m² bid d1-21
Study NCT04170426 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: autologous adipose derived stem cells
Description: Culture expanded mesenchymal stem cells isolated from patient's own abdominal fat tissue
Study NCT05880654 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Scaling & root planning
Description: Non Surgical periodontal therapy
Study NCT06216483 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: PDM Alert
Description: passive digital marker (PDM) for postoperative delirium risk
Study NCT06216483 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PDM Alert
Description: passive digital marker (PDM) for postoperative delirium risk
Study NCT06453447 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablet (cellulose) PO once daily for 14 days starting day of surgery
Study NCT05624554 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nemtabrutinib
Description: 65 mg administered orally daily until disease progression, unacceptable toxicity, or discontinuation criteria met.
Study NCT05624554 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fludarabine
Description: 25 mg/m\^2 administered via intravenous (IV) infusion on Days 1, 2, and 3 of each 28-day cycle up to 6 cycles.
Study NCT05624554 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: 250 mg/m\^2 administered via IV infusion on Days 1, 2, and 3 of each 28-day cycle up to 6 cycles.
Study NCT05624554 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bendamustine
Description: Administered via IV infusion on Days 1 and 2 of each 28-day cycle up to 6 cycles. The first dose is given as 70 to 90 mg/m\^2. Subsequent doses may be escalated up to 90 mg/m\^2, if applicable and as per local guidelines.
Study NCT05624554 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab
Description: Administered as an IV infusion on Day 1 of each 28-day cycle. The initial dose is 375 mg/m\^2 (cycle 1) followed by 500 mg/m\^2 for remaining cycles.
Study NCT04170426 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: autologous adipose derived stem cells
Description: Culture expanded mesenchymal stem cells isolated from patient's own abdominal fat tissue
Study NCT05624554 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Truxima
Description: Administered as an IV infusion on Day 1 of each 28-day cycle. The initial dose is 375 mg/m\^2 (cycle 1) followed by 500 mg/m\^2 for remaining cycles.
Study NCT06275412 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The 3Ms 2.0 Intervention
Description: The 3Ms is a culturally tailored, mHealth intervention for primary caregivers of Black adolescents with T1D focused on promoting daily parental monitoring of adolescent diabetes care and delivered via an Internet platform, Computer Intervention Authoring System (CIAS). The intervention content is based on the Information-Motivation-Behavioral Skills (IMB) model. Caregivers randomized to The 3Ms receive 3 sessions. The caregiver is guided through each session by an interactive and emotive three-dimensional narrator that reads and speaks aloud. Additional intervention content includes brief videoclips to provide skills demonstrations of supportive parenting practices related to diabetes care and text message reminders. Each session is no more than 20 minutes in length. The intervention is delivered over a three-month window, with the two follow-up sessions available to be accessed by the caregiver at one-month intervals after completion of the initial session.
Study NCT05624554 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Ruxience
Description: Administered as an IV infusion on Day 1 of each 28-day cycle. The initial dose is 375 mg/m\^2 (cycle 1) followed by 500 mg/m\^2 for remaining cycles.
Study NCT05624554 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Riabni
Description: Administered as an IV infusion on Day 1 of each 28-day cycle. The initial dose is 375 mg/m\^2 (cycle 1) followed by 500 mg/m\^2 for remaining cycles.
Study NCT06275412 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Educational Attention Control (EAC)
Description: The EAC intervention consists of three sessions delivered in an mHealth format via the CIAS internet platform over three months, with access for a maximum of six months. EAC provides structured information on topics of interest to caregivers of adolescents with T1D such as travelling with diabetes, or emergency preparedness for persons with diabetes. All participants receive their standard medical care.
Study NCT06080425 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Medical Nutrition Therapy
Description: Counselling
Study NCT05014828 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lenvatinib
Description: Capsules administered orally
Study NCT05915923 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 1 Hz Repetitive transcranial magnetic stimulation
Description: After enrollment, healthy adults received rTMS once a day (stimulation plan: stimulation of M1 region on the dominant hemisphere at 1Hz)
Study NCT05915923 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 10 Hz Repetitive transcranial magnetic stimulation
Description: After enrollment, healthy adults received rTMS once a day (stimulation plan: stimulation of M1 region on the dominant hemisphere at 10Hz)
Study NCT05915923 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham Repetitive transcranial magnetic stimulation
Description: After enrollment, healthy adults received sham-rTMS once a day with the same parameters as the 10 Hz rTMS group, but the coil rotated 90° away from the scalp
Study NCT06106152 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: WTX212A injection
Description: The WTX212A infusion is given every 21 days
Study NCT06106152 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD -1/PD-L1 monoclonal antibody
Description: The PD -1/PD-L1 monoclonal antibody is given every 21 days
Study NCT06033209 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SMNP (SC, Fractioned)
Description: SC in the upper arm, Fractionated escalating dose for prime
Study NCT06076213 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Artesunate-amodiaquine
Description: Tablets
Study NCT06076213 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Artemether-lumefantrine
Description: Tablets
Study NCT05014828 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: intravenous (iv) infusion
Study NCT06422208 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous midbrain dopamine neurons
Description: The autologous midbrain dopamine neurons are a experimental cryopreserved cell product derived from human autologous induced pluripotent stem cells. The autologous midbrain dopamine neurons will be surgically administered into the putamen, unilaterally, in a single surgical session.
Study NCT06241014 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mulligan Mobilization and Sling Exercises
Description: Mulligan mobilizations along with sling exercises. Mulligan mobilizations include SNAGs. Participants will receive 3 sets of mulligan mobilization techniques per session, each set involving 10 times repetition of the exercise. The interval between the sets will be 15 to 20 seconds. The technique will be repeated total of six times having two sessions per week for 3 weeks. For the sling exercise, the sling exercise program will also be applied for 3 weeks, 2 times a week for 20 minutes per day. To perform the exercise, the subjects will be instructed with a demonstration and explanation.
Study NCT05992324 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Caption LungAI
Description: Caption LungAI is a software that is designed to help non-expert healthcare professionals acquire diagnostic quality images on an 8-zone lung protocol for both healthy patients and patients presenting with pathology such as B-Lines.
Study NCT04950166 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pegsitacianine
Description: An intraoperative nanoparticle-based fluorescence imaging agent comprised of micelles covalently conjugated to indocyanine green (ICG).
Study NCT04472260 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Verticalization and Prone position
Description: The randomly selected study sequence (Arm1, Arm2, Arm3 or Arm4) will begin after the supine roll-over at the end of the first PP session (out-of-study sequence). This allows all patients to initially have the positioning technique that has been proven beneficial in ARDS.~The chronology of the treatment periods in each of the 4 arms allocated by randomization will be as follows: Each PP must be started within 4 to 8 hours after the end of the previous PP or after the end of the verticalization that just preceded it. Each verticalization must be performed within 4 to 8 hours after the end of the previous PP or the previous verticalization. Each PP period will last between 12 and 20 hours.
Study NCT02747303 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stereotactic Radiosurgery
Description: The SRS dose will depend on the maximum diameter of the gross tumor volume (GTV)
Study NCT02747303 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Stereotactic Radiosurgery
Description: The SRS dose will depend on the maximum diameter of the gross tumor volume (GTV)
Study NCT06036914 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bumetanide
Description: Bumetanide will be administered via intravenous (IV) infusion at a dose of 12.5 mg two times a day (BID) for 2 doses total within 24 hours.
Study NCT06036914 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Furosemide
Description: Furosemide will be administered via intravenous (IV) infusion at usual doses (twice the home dose of oral daily diuretic in furosemide equivalents) administered as 2 doses total within 24 hours.~Furosemide equivalents will be considered as follows (40 mg of intravenous furosemide = 1 mg oral bumetanide or 40 mg of torsemide or 80 mg of oral furosemide consistent with prior literature). The lowest dose of furosemide administered during the study will be 40 mg IV two times a day (BID) and the maximum dose will be 100 mg IV BID.
Study NCT05060887 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: OVX836-003
Description: One single administration intramuscularly at Day 1.
Study NCT05060887 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Saline solution
Description: One single administration intramuscularly at Day 1.
Study NCT05146973 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 177Lu-DOTA-TLX591
Description: TLX591, a monoclonal antibody conjugated with a DOTA chelator and radiolabelled with 177Lu (177Lu-DOTA-TLX591)
Study NCT06004882 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PNS therapy
Description: PNS therapy-NS is a 60-day therapy targeting chronic pain. The procedure involves implanting a small piece of wire next to the nerve causing pain, and the wire is connected to an external device that is then used to apply electric pulses to the nerve, blocking pain signals, for 60 days
Study NCT06004882 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triamcinolone
Description: Given by Injection
Study NCT06004882 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Description: Given by Injection
Study NCT06241014 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Mulligan Mobilization
Description: Mulligan Mobilization
Study NCT06559540 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Hypofractionated radiation
Description: External beam photon therapy with IMRT or VMAT to the breast/chestwall and regional lymph nodes, including supraclavicular, infraclavicular, axillary, and internal mammary nodes,
Study NCT06559540 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Ultra-hypofractionated breast/chest wall and regional nodal radiation
Description: External beam photon therapy with IMRT or VMAT to the breast/chestwall and regional lymph nodes, including supraclavicular, infraclavicular, axillary, and internal mammary nodes
Study NCT06004882 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Given by Injection
Study NCT05926739 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Electrical stimulation and biofeedback with Phenix Liberty medical device
Description: 12 sessions of electrical stimulation and biofeedback performed between 6 and 8 weeks at regular intervals according to a schedule drawn up by the physiotherapist.~The patient will undergo 12 therapeutic functional reeducation sessions, at regular intervals according to a schedule drawn up by the physiotherapist, during which the PHENIX LIBERTY device may be used. The patients will complete questionnaires at the end of the care.~Overall, the functional rehabilitation sessions will include muscle testing, electrostimulation and biofeedback.~The follow up will be conduct as follow :~* 12 sessions between 6 and 8 weeks~* 1 end visit, within the week after the 12th session
Study NCT04170426 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: autologous adipose derived stem cells
Description: Culture expanded mesenchymal stem cells isolated from patient's own abdominal fat tissue
Study NCT04162171 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiotherapy (SBRT) ablation of VT
Description: Additional imaging for SBRT planning and implementation:~* Planning CT (pCT) - CT simulator that utilizes a respiratory positioning monitoring (RPM) optical tracking system and SBRT immobilization setup to provide necessary data to allow for monitoring of the patient's deep inspiration breath-hold (DIGH) maneuver during treatment delivery.~* SBRT treatment - 30 min procedure on a TrueBeam 1 linear accelerator using SBRT fixation. Patient alignment and DIBH maneuver from the pCT will be replicated using the on-board cone-beam CT (CBCT) guidance and RPM systems.
Study NCT05610007 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prilocaine
Description: Patients in the prilocaine group were given 50 mg hyperbaric 2% prilocaine (2.5 ml volume) + 25 mcg fentanyl (0.5 ml volume) before undergoing the cystoscopy procedure.
Study NCT05610007 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prilocaine
Description: Patients in the prilocaine group were given 50 mg hyperbaric 2% prilocaine (2.5 ml volume) + 25 mcg fentanyl (0.5 ml volume) before undergoing the cystoscopy procedure.
Study NCT05460169 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Renal denervation
Description: The Paradise® Renal Denervation System (Paradise System) is CE-marked in countries accepting the CE mark. The system is a catheter-based device designed to use ultrasound energy to thermally ablate the afferent and efferent nerves surrounding the renal artery and serving the kidney.